{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:39:16Z","timestamp":1790127556503,"version":"4.0.1"},"reference-count":77,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2014.00668","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T10:32:47Z","timestamp":1420453967000},"source":"Crossref","is-referenced-by-count":16,"title":["Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab"],"prefix":"10.3389","volume":"5","author":[{"given":"Caroline","family":"Antoniol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u00e2\u20ac\u2122s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00415-012-6759-0","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab","volume":"260","author":"Mc Govern","year":"2013","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","article-title":"MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy","volume":"83","author":"Phan-Ba","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308630","article-title":"MRI pattern in asymptomatic natalizumab-associated PML","author":"Wattjes","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fneur.2013.00011","article-title":"Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy","volume":"4","author":"Lind\u00c3\u00a5","year":"2013","journal-title":"Front Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/1352458508096870","article-title":"Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA","volume":"15","author":"Iacobaeus","year":"2009","journal-title":"Mult Scler"},{"issue":"6","key":"B14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00c3\u00b8rensen","year":"2012","journal-title":"Mult Scler"},{"key":"B16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"issue":"185","key":"B17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.4049\/jimmunol.0904209","article-title":"Direct CD4 help provision following interaction of memory CD4 and CD8 T cells with distinct antigen-presenting dendritic cells","volume":"1950","author":"de Go\u00c3\u00abr de Herve","year":"2010","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/00002030-200307040-00004","article-title":"Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy","volume":"17","author":"Gasnault","year":"2003","journal-title":"AIDS"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifoca leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1352458510385834","article-title":"CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus","volume":"17","author":"Warnke","year":"2011","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ana.21443","article-title":"Detection of JC virus DNA fragments but not proteins in normal brain tissue","volume":"64","author":"Perez-Liz","year":"2008","journal-title":"Ann Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9200","DOI":"10.1128\/JVI.00609-10","article-title":"JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy","volume":"84","author":"Tan","year":"2010","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1177\/1352458512466165","article-title":"Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab \u00e2\u20ac\u0153infusion group\u00e2\u20ac\u009d","volume":"19","author":"Havla","year":"2013","journal-title":"Mult Scler"},{"key":"B24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli","year":"2009","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/1743-422X-10-298","article-title":"Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study","volume":"10","author":"Bellizzi","year":"2013","journal-title":"Virol J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jneuroim.2011.02.010","article-title":"Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients","volume":"235","author":"Skarica","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e34493","DOI":"10.1371\/journal.pone.0034493","article-title":"Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient","volume":"7","author":"Sottini","year":"2012","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","article-title":"Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy","volume":"72","author":"St\u00c3\u00bcve","year":"2009","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201142108","article-title":"Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis","volume":"42","author":"Planas","year":"2012","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1352458511421919","article-title":"Immunological and clinical consequences of treating a patient with natalizumab","volume":"18","author":"Schwab","year":"2012","journal-title":"Mult Scler"},{"key":"B32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00c3\u00bcve","year":"2006","journal-title":"Ann Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1084\/jem.20140540","article-title":"VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells","volume":"211","author":"Schneider-Hohendorf","year":"2014","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab","volume":"65","author":"del Pilar Martin","year":"2008","journal-title":"Arch Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e34103","DOI":"10.1371\/journal.pone.0034103","article-title":"Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis","volume":"7","author":"de Andr\u00c3\u00a9s","year":"2012","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2013.00283","article-title":"Tissue competence imprinting and tissue residency of CD8 T cells","volume":"4","author":"Krzysiek","year":"2013","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e36779","DOI":"10.1371\/journal.pone.0036779","article-title":"Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis","volume":"7","author":"Link","year":"2012","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1004084","DOI":"10.1371\/journal.ppat.1004084","article-title":"JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants","volume":"10","author":"Sundqvist","year":"2014","journal-title":"PLoS Pathog"},{"key":"B39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/JVI.70.10.7004-7012.1996","article-title":"JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency","volume":"70","author":"Monaco","year":"1996","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ana.24148","article-title":"JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis","volume":"75","author":"Chalkias","year":"2014","journal-title":"Ann Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000302687","article-title":"Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells","volume":"63","author":"Putzki","year":"2010","journal-title":"Eur Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ana.410310426","article-title":"Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy","volume":"31","author":"Tornatore","year":"1992","journal-title":"Ann Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamaneurol.2014.1855","article-title":"Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis","volume":"71","author":"Warnke","year":"2014","journal-title":"JAMA Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1086\/653824","article-title":"The curious incident of the dog in the nighttime: does the absence of virus replication in Epstein-Barr virus-transformed B cells point to an important feature of JC virus biology?","volume":"202","author":"Houff","year":"2010","journal-title":"J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2165\/11537510-000000000-00000","article-title":"Progressive multifocal leukoencephalopathy and newer biological agents","volume":"33","author":"Berger","year":"2010","journal-title":"Drug Saf"},{"key":"B48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCVTM DxSelectTM) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1099\/vir.0.18842-0","article-title":"Seroepidemiology of the human polyomaviruses","volume":"84","author":"Stolt","year":"2003","journal-title":"J Gen Virol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean","year":"2009","journal-title":"PLoS Pathog"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"B53","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40263-014-0168-0","article-title":"Natalizumab: risk stratification of individual patients with multiple sclerosis","volume":"28","author":"Tur","year":"2014","journal-title":"CNS Drugs"},{"key":"B55","article-title":"Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 \u00ce\u00b1-chain (CD11a) in MS patients","author":"Jilek","year":"2013","journal-title":"Mult Scler"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1084\/jem.20110434","article-title":"Th17 lymphocytes traffic to the central nervous system independently of \u00ce\u00b14 integrin expression during EAE","volume":"208","author":"Rothhammer","year":"2011","journal-title":"J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","article-title":"Fatal PML associated with efalizumab therapy: insights into integrin \u00ce\u00b1L\u00ce\u00b22 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev.cellbio.042308.113238","article-title":"Rolling cell adhesion","volume":"26","author":"McEver","year":"2010","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1074-7613(01)00110-8","article-title":"CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis","volume":"14","author":"Grewal","year":"2001","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejcb.2011.02.007","article-title":"L-selectin \u00e2\u20ac\u201c a dynamic regulator of leukocyte migration","volume":"91","author":"Wedepohl","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1128\/JVI.00131-13","article-title":"Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy","volume":"87","author":"Hendel-Chavez","year":"2013","journal-title":"J Virol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins","year":"2012","journal-title":"PLoS Pathog"},{"issue":"186","key":"B65","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.4049\/jimmunol.1003309","article-title":"Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure","volume":"1950","author":"Miconnet","year":"2011","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/brain\/awh119","article-title":"Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution","volume":"127","author":"Laplaud","year":"2004","journal-title":"Brain J Neurol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0165-5728(02)00105-4","article-title":"Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing-remitting MS","volume":"127","author":"Muraro","year":"2002","journal-title":"J Neuroimmunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1212\/WNL.0b013e3182a84101","article-title":"Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis","volume":"81","author":"Warnke","year":"2013","journal-title":"Neurology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"810","DOI":"10.7150\/ijms.8647","article-title":"Expression, regulation and function of microRNAs in multiple sclerosis","volume":"11","author":"Ma","year":"2014","journal-title":"Int J Med Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","article-title":"Regulation of mRNA translation and stability by microRNAs","volume":"79","author":"Fabian","year":"2010","journal-title":"Annu Rev Biochem"},{"key":"B71","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fgene.2012.00311","article-title":"microRNA dysregulation in multiple sclerosis","volume":"3","author":"Jr Ode","year":"2012","journal-title":"Front Genet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clim.2012.04.002","article-title":"Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects","volume":"144","author":"Sievers","year":"2012","journal-title":"Clin Immunol"},{"issue":"14","key":"B73","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1177\/1352458514534513","article-title":"Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"20","author":"Mu\u00c3\u00b1oz-Culla","year":"2014","journal-title":"Mult Scler"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1177\/1352458514524998","article-title":"MiR-126: a novel route for natalizumab action?","volume":"20","author":"Meira","year":"2014","journal-title":"Mult Scler"},{"key":"B75","doi-asserted-by":"publisher","first-page":"18704","DOI":"10.1073\/pnas.0905063106","article-title":"Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease","volume":"106","author":"Mattes","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B76","doi-asserted-by":"publisher","first-page":"11665","DOI":"10.1073\/pnas.0509430103","article-title":"The Ets factor Spi-B is a direct critical target of the coactivator OBF-1","volume":"103","author":"Bartholdy","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1099\/vir.0.023184-0","article-title":"Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter\/enhancer of JC virus and supports viral activity","volume":"91","author":"Marshall","year":"2010","journal-title":"J Gen Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T12:46:52Z","timestamp":1598618812000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2014.00668\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,5]]},"references-count":77,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2014.00668","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,5]]}}}